3-Methyl-8-Quinolinesulphonyl Chloride CAS 74863-82-4 Argatroban Entèmedyè Faktori 98.0%
Manifakti Pwovizyon pou Argatroban Entèmedyè ki gen rapò:
Ethyl (2R,4R)-4-Methyl-2-Piperidinecarboxylate CAS 74892-82-3
N-Nitro-1,2,3,4-tetradehydro Argatroban Ethyl Ester CAS 74874-09-2
3-Methyl-8-Quinolinesulphonyl Chloride CAS 74863-82-4
Argatroban monoidrat CAS 141396-28-3
Argatroban anidrid CAS 74863-84-6
Non Chimik | 3-Methyl-8-Quinolinesulphonyl klori |
Sinonim | 3-Methylquinoline-8-Sulfonyl klori |
Nimewo CAS | 74863-82-4 |
Nimewo CAT | RF-PI269 |
Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
Fòmil molekilè | C10H8ClNO2S |
Pwa molekilè | 241.69 |
Dansite | 1.4±0.1 g/cm3 |
Endèks refraktif | 1.63 |
Solibilite | Soluble nan klowofòm |
Kondisyon Shipping | Anba tanperati anbyen |
Mak | Ruifu Chimik |
Atik | Espesifikasyon |
Aparans | White Crystalline Powder |
Pite / Metòd analiz | >98.0% (HPLC) |
Pwen k ap fonn | 162.0 ~ 163.0 ℃ |
Pèt sou siye | <0.50% |
3-Methylquinoline-8-Sulfonic Asid | <1.00% |
Enpurte total | <2.00% |
Enfrawouj Spectrum | Konfòm ak estrikti |
RMN | Konfòm ak estrikti |
Tès Creole | Enterprise Standard |
Itilizasyon | Entèmedyè nan Argatroban (CAS 74863-84-6) |
Pake: Boutèy, sak papye aliminyòm, 25kg / tanbou katon, oswa selon kondisyon kliyan an
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite
Shanghai Ruifu Chemical Co, Ltd se manifakti dirijan ak founisè nan klori 3-Methyl-8-Quinolinesulphonyl (CAS: 74863-82-4) ak kalite siperyè, lajman ki itilize nan sentèz òganik, sentèz entèmedyè pharmaceutique ak engredyan aktif famasetik. (API) sentèz.Lise yon entèmedyè tipikman nan sentèz Argatroban (CAS: 74863-84-6) oswa Argatroban Monohydrate (CAS 141396-28-3).
Argatroban (CAS: 74863-84-6) se yon anticoagulant ki se yon ti molekil inibitè tronbin dirèk.An 2000, Administrasyon Manje ak Medikaman (FDA) te otorize argatroban pou pwofilaktik oswa tretman tronboz nan pasyan ki gen tronbositopeni eparin-induced (HIT).An 2002, li te apwouve pou itilize pandan entèvansyon perkutane kowonè nan pasyan ki gen HIT oswa ki gen risk pou yo devlope li.Nan 2012, li te apwouve pa MHRA nan UK a pou antikoagulasyon nan pasyan ki gen tronbositopeni eparin-induit tip II (HIT) ki bezwen terapi antithrombotic parenteral.